Oxurion NV: Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes

Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edemaand Announces Board Changes Trial has now enrolled more

Related Keywords

United States ,Netherlands ,Israel ,Belgium ,Tel Aviv ,Boston ,Massachusetts ,Leuven ,Region Flamande ,Amsterdam ,Noord Holland ,Israeli ,Dutch ,Dennis Riedl ,Tom Graney ,Michael Dillen ,Pkal Inhibitor ,Nathalie Laarakker ,Maryt Conway ,David Guyer ,Sidney Fox ,Christopher Brinzey ,Company Annual ,Ophthalmology At Tel Aviv University ,Company Board Of Directors ,Michelson Award Of The Macula Society ,Israeli Ophthalmological Society ,Macula Society Arnall Patz Medal ,University Of Amsterdam ,Data Monitoring Committee ,Ophthalmology At Sourasky Medical Center ,Conway Communications ,Department Of Ophthalmology ,Tel Aviv Medical Center ,Oxurion Provides Updateon Recruitment ,Partb Trial ,Diabetic Macular ,Announces Board ,Interim Analysis Outcome ,Euronext Brussels ,Independent Data Monitoring Committee ,Andy De Deene ,Chief Development Officer ,Adrienne Graves ,Anat Loewenstein ,Chief Financial Officer ,General Secretary ,Sidney Fox Chair ,Tel Aviv University ,Sourasky Medical ,Ophthalmology Power ,Michelson Award ,Macula Society ,Rosenthal Award ,Arnall Patz Medal ,Annual General Shareholders Meeting ,Macular Edema ,Optical Coherence Tomography ,Central Subfield Thickness ,Oxurion ,Rovides ,Update ,Recruitment ,Kalahari ,Hase ,Art ,Trial ,Novel ,Makal ,Inhibitor ,Diabetic ,Macular ,Bedema ,Nnounces ,Board ,Changes ,